Nasdaq · CIK 0001661059
NXTC NextCure, Inc.
Insider trading from SEC Form 4. Last filing Aug 12, 2026. Close $6.64 on Oct 12, 2026, +315% from the 52-week low and -53% from the high.
In brief
NextCure, Inc. (NXTC) has 24 SEC Form 4 filings on file from 14 insiders, the latest filed on Aug 12, 2026. In the last 90 days insiders made 2 open-market buys worth $1.7M and 1 open-market sell worth $185k, net +$1.5M.
3 open-market trades have been scored at NXTC. The newest: Simcere Zaiming, Inc. sold $185k of stock on Aug 10, 2026, filed Aug 12, 2026, scored 30 (weak). The largest of the 3 shown: ADAR1 Capital Management, LLC (10% owner) bought $1.6M on Jul 30, 2026, scored 47 (moderate).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NextCure, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Simcere Zaiming, Inc. other sell | $185k 30,000 shares | -9% | - | |
| 47Moderate | ADAR1 Capital Management, LLC owner buy | $1.6M 329,153 shares | +84% | - | |
| 16Weak | ADAR1 Capital Management, LLC owner buy | $88k 17,608 shares | +5% | - |
Transactions
Every row filed, 35 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Simcere Zaiming, Inc. other | SOpen-market sale Common Stockindirect: See Footnotes | -30,000 | $6.16 | $185k | 308,636 | Aug 12, 2026 |
| Jul 30, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +50,000 | $4.97 | $249k | 443,266 | Aug 3, 2026 |
| Jul 30, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +20,000 | $5.00 | $100k | 463,266 | Aug 3, 2026 |
| Jul 30, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +20,000 | $5.00 | $100k | 483,266 | Aug 3, 2026 |
| Jul 30, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $4.81 | $120k | 508,266 | Aug 3, 2026 |
| Jul 30, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +100,000 | $4.90 | $490k | 608,266 | Aug 3, 2026 |
| Jul 30, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +77,850 | $4.96 | $386k | 686,116 | Aug 3, 2026 |
| Jul 31, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +3,300 | $4.98 | $16k | 689,416 | Aug 3, 2026 |
| Jul 31, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $4.98 | $125k | 714,416 | Aug 3, 2026 |
| Jul 31, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +8,003 | $4.80 | $38k | 722,419 | Aug 3, 2026 |
| Jul 27, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +7,798 | $5.00 | $39k | 383,456 | Jul 29, 2026 |
| Jul 28, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +6,400 | $4.95 | $32k | 389,856 | Jul 29, 2026 |
| Jul 29, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +1,810 | $5.00 | $9,050 | 391,666 | Jul 29, 2026 |
| Jul 29, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +1,600 | $5.00 | $8,000 | 393,266 | Jul 29, 2026 |
| Jun 18, 2026 | Elaine Jones V director | AGrant or award Stock Option (Right to Buy)derivative | +2,340 | $0.00 | $0 | 2,340 | Jun 22, 2026 |
| Jun 18, 2026 | Stephen W Webster director | AGrant or award Stock Option (Right to Buy)derivative | +2,340 | $0.00 | $0 | 2,340 | Jun 22, 2026 |
| Jun 18, 2026 | David S Kabakoff director | AGrant or award Stock Option (Right to Buy)derivative | +3,510 | $0.00 | $0 | 3,510 | Jun 22, 2026 |
| Jun 18, 2026 | Ellen Feigal director | AGrant or award Stock Option (Right to Buy)derivative | +2,340 | $0.00 | $0 | 2,340 | Jun 22, 2026 |
| Jun 18, 2026 | Anne Elizabeth Borgman director | AGrant or award Stock Option (Right to Buy)derivative | +2,340 | $0.00 | $0 | 2,340 | Jun 22, 2026 |
| Jun 18, 2026 | John G Houston director | AGrant or award Stock Option (Right to Buy)derivative | +2,340 | $0.00 | $0 | 2,340 | Jun 22, 2026 |
| Jan 30, 2026 | Steven P. Cobourn Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +14,670 | $0.00 | $0 | 14,670 | Feb 3, 2026 |
| Jan 30, 2026 | Udayan Guha Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +14,670 | $0.00 | $0 | 14,670 | Feb 3, 2026 |
| Jan 30, 2026 | Sourav Kundu Sr VP, Dev. & Mfg. | AGrant or award Employee Stock Option (Right to Buy)derivative | +8,270 | $0.00 | $0 | 8,270 | Feb 3, 2026 |
| Jan 30, 2026 | Timothy Mayer Chief Operating Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +14,670 | $0.00 | $0 | 14,670 | Feb 3, 2026 |
| Jan 30, 2026 | Michael Richman President & CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +38,190 | $0.00 | $0 | 38,190 | Feb 3, 2026 |
| Jan 30, 2026 | Kevin G. Shaw Sr VP, General Counsel | AGrant or award Employee Stock Option (Right to Buy)derivative | +8,270 | $0.00 | $0 | 8,270 | Feb 3, 2026 |
| Jun 20, 2025 | Anne Elizabeth Borgman director | AGrant or award Stock Option (Right to Buy)derivative | +18,700 | $0.00 | $0 | 18,700 | Jun 24, 2025 |
| Jun 20, 2025 | Stephen W Webster director | AGrant or award Stock Option (Right to Buy)derivative | +18,700 | $0.00 | $0 | 18,700 | Jun 24, 2025 |
| Jun 20, 2025 | David S Kabakoff director | AGrant or award Stock Option (Right to Buy)derivative | +28,050 | $0.00 | $0 | 28,050 | Jun 24, 2025 |
| Jun 20, 2025 | Elaine Jones V director | AGrant or award Stock Option (Right to Buy)derivative | +18,700 | $0.00 | $0 | 18,700 | Jun 24, 2025 |
| Jun 20, 2025 | John G Houston director | AGrant or award Stock Option (Right to Buy)derivative | +18,700 | $0.00 | $0 | 18,700 | Jun 24, 2025 |
| Jun 20, 2025 | Ellen Feigal director | AGrant or award Stock Option (Right to Buy)derivative | +18,700 | $0.00 | $0 | 18,700 | Jun 24, 2025 |
| Jan 31, 2025 | Steven P. Cobourn Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +117,375 | $0.00 | $0 | 117,375 | Feb 3, 2025 |
| Jan 31, 2025 | Sourav Kundu Sr VP, Dev. & Mfg. | AGrant or award Employee Stock Option (Right to Buy)derivative | +66,125 | $0.00 | $0 | 66,125 | Feb 3, 2025 |
| Jan 31, 2024 | Steven P. Cobourn Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +117,375 | $0.00 | $0 | 117,375 | Feb 1, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- ADAR1 Capital Management, LLCowner
- Anne Elizabeth Borgmandirector, officer
- Steven P. CobournChief Financial Officer
- Ellen Feigaldirector
- Udayan GuhaChief Medical Officer
- John G Houstonceo, president, officer, director
- Elaine Jones Vdirector
- David S Kabakoffdirector
- Sourav KunduSr VP, Dev. & Mfg.
- Timothy MayerChief Operating Officer
- Michael RichmanPresident & CEO
- Kevin G. ShawSr VP, General Counsel
- Simcere Zaiming, Inc.other
- Stephen W Websterdirector
Questions about NXTC
Answered from the filings on this page, as of the latest one.
Are insiders buying NXTC?
As of Aug 12, 2026, SEC Form 4 filings show 2 open-market buys worth $1.7M by 1 insider and 1 open-market sell worth $185k by 1 insider at NextCure, Inc. in the last 90 days, net +$1.5M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade NXTC on the open market?
Simcere Zaiming, Inc. sold $185k of NXTC on Aug 10, 2026 and filed the Form 4 on Aug 12, 2026. InsiderTell scored 30 (weak).
How many insiders file Form 4 at NextCure, Inc.?
14 people have filed a Form 4 at NextCure, Inc., among them ADAR1 Capital Management, LLC (10% owner), Anne Elizabeth Borgman (director and officer), Steven P. Cobourn (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.